REGiM - A randomised controlled trial of prolonged treatment with darbepoetin alpha (EPO), with or without recombinant human granulocyte colony stimulating factor (G-CSF), versus best supportive care in patients with low-risk myelodysplastic syndromes (MDS).

Trial Profile

REGiM - A randomised controlled trial of prolonged treatment with darbepoetin alpha (EPO), with or without recombinant human granulocyte colony stimulating factor (G-CSF), versus best supportive care in patients with low-risk myelodysplastic syndromes (MDS).

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2016

At a glance

  • Drugs Darbepoetin alfa (Primary) ; Filgrastim (Primary)
  • Indications Aplastic anaemia; Neutropenia; Refractory anaemia; Sideroblastic anaemia
  • Focus Therapeutic Use
  • Acronyms REGiM
  • Most Recent Events

    • 27 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 30 Jun 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top